key: cord-1024098-om8njbmw authors: Chatterjee, Saptarshi title: Status of Remdesivir: Not Yet Beyond Question! date: 2020-09-21 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.09.004 sha: 09dcc01e33427725cad56872e81a357d625bf6bc doc_id: 1024098 cord_uid: om8njbmw nan To the Editor, This is in response to a recently published article in your journal titled ''Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More'' by Saha A, et al. 2020 (1) . The authors have beautifully placed the plausible molecular mechanism of action of Remdesivir, a broad spectrum of antiviral drug. The phrase in the title 'Need to know more' provoked me to clarify a fact and comment on the status of Remdesivir. Remdesivir, has appropriately been commented as 'molecule of hope' yet is not beyond question in terms of safety. 'USFDA approved this drug for treatment COVID-19' used by authors might be a futuristic comment since Remdesivir has not yet been approved by USFDA. On May 1, 2020, the USFDA has provided Emergency Use Authorization (EUA) and permits the emergency use of the drug for the treatment of suspect and laboratory confirmed COVID 19 case in adult and children hospitalized with severe disease (2) . This allows Gilead, to produce and distribute the drug for the prescribed purpose. The distinction between USFDA 'Approved' and 'EUAs' itself signifies the fact that clinical data is still insufficient call the drug as 'safe'. Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives (3). Though Remdesivir must be administered by intravenous infusion, as suggested by USFDA, the optimal duration of treatment is not known. Moreover, the drug is not supposed to be used as prophylactic or therapeutic mode outside hospital set-up. Moreover, communicating patient with fact sheet, hepatic laboratory testing prior to administration is to be done and patients with known hypersensitivity to any ingredient of Remdesivir must not be treated with the said drug. Remdesivir (GS-5734), a nucleoside analogue prodrug has shown inhibitory effect on SARS-CoC-1, SARS-CoV-2 and MERS in animal model (4) . However, randomized, double placebo-controlled, multicenter trial showed nonsignificant role of Remdesivir in context to clinical improvement, mortality or even time to clearance of virus in compared to placebo (5) 28 Clinical studies are reported with Remdesivir in the Clinical Trial registry (ClinicalTrial. gov) out of which 20 are of interventional type. Phase II and Phase III has been reached by 12 each clinical study (6) . Recently, Gilead announced the result of Phase III clinical trial on Remdesivir that demonstrated similar efficacy with 5 and 10 d dosing duration of the drug (7). There are several safety concerns, risk and uncertainty yet to be eliminated for the success of the drug. Hence, the medical community should not be misled as Remdesivir is still not USFDA drug being out of question and is presently applicable for compassionate-use as investigational drug. The unintentional wordings of the authors as approved by USFDA, if succeeds in near future through evidences of clinical trial, would definitely bring a relief to scientific/medical community as a solution to COVID 19. None. Probable molecular mechanism of Remdesivir for the treatment of COVID-19: need to know more USFDA: letter of EUA Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial None.